Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV13 alternative and reduced infant immunization schedule study
NL-OMON35410Phase 4Active, not recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Jun 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease (4 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoints: Serotype-specific pneumococcal antibody concentrations at 12 months, Geometric mean concentrations at 12 months and 1 more. Started Jun 2010; status: active, not recruiting.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NL-OMON35410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35410.